Retatrutide
100% Online — No Office Visit Required
Retatrutide is an emerging triple-agonist medication (GLP-1, GIP, and glucagon) that has shown significant weight loss in early-phase clinical trials — potentially exceeding results seen with tirzepatide.
What Is Retatrutide?
Retatrutide activates three receptors — GLP-1, GIP, and glucagon — making it the first triple-agonist in this class. Early clinical data suggests weight loss outcomes that may exceed those of tirzepatide, though full regulatory approval is pending.
Who May Be a Candidate
As of 2026, retatrutide is still in clinical trials. Availability through OakMD depends on regulatory status and individual provider assessment. Your care team can provide the most current information.
How OakMD Works
OakMD is a telemedicine platform connecting eligible adults with licensed providers. If you're interested in Retatrutide, the process begins with a brief online intake form. A licensed provider will review your health history, symptoms, and goals — and determine if treatment is appropriate for you.
If you are a candidate, your provider will create a personalized treatment plan and guide you through next steps. There are no in-person visits required.
Common Questions
Is retatrutide available now?
Availability depends on current regulatory status and compounding pharmacy access. Your OakMD care team can provide the most current information about availability.
Ready to Get Started?
Complete a brief online intake. A licensed provider will review your information and determine if treatment is appropriate for you.
Medical Disclaimer: The information on this page is provided for educational purposes only and does not constitute medical advice. OakMD is a telemedicine platform. All treatments are prescription-based, subject to provider review, and may not be appropriate for all individuals. A licensed provider will evaluate your medical history and determine eligibility. Consult a qualified healthcare professional before starting any new treatment.